Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis
Open Access
- 16 April 2017
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 72 (7) , 1871-1879
Abstract
Objectives: To estimate the prevalence of adverse drug reactions or events (ADR) during drug-resistant TB (DR-TB) treatment in the context of settings with high HIV prevalence (at least 20% of patients). Methods: We conducted a systematic review and meta-analysis of articles in PubMed and Scopus. Pooled proportions of patients experiencing adverse events and relative risk with 95% CI were calculated. Results: The search yielded 24 studies, all observational cohorts. Ten reported on the number of patients experiencing ADR and were included in the meta-analysis representing 2776 study participants of whom 1943 were known to be HIV infected (70.0%). An average of 83% (95% CI: 82%–84%) of patients experienced one or more ADR. Among the seven articles (n = 664 study participants) with information on occurrence of severe ADR, 24% (95% CI: 21%–27%) of patients experienced at least one severe ADR during drug-resistant TB treatment. Sixteen of the 24 studies analysed the relative risk of ADR by HIV infection, nine of which found no statistically significant association between HIV infection and occurrence of drug-related ADR. There was insufficient information to disaggregate risk by concomitant treatment with HIV antiretrovirals or by immunosuppression (CD4 count). Conclusions: No randomized clinical trials were found for WHO-recommended treatment of drug-resistant TB treatment where at least 20% of the cohort was coinfected with HIV. Nearly all patients (83%) experience ADR during DR-TB treatment. While no significant association between ADR and HIV coinfection was found, further research is needed to determine whether concomitant antiretrovirals or immunosuppression increases the risks for HIV-infected patients.Keywords
This publication has 31 references indexed in Scilit:
- Adverse Events Associated With the Treatment of Multidrug-Resistant TuberculosisAmerican Journal of Therapeutics, 2016
- Health status and quality of life in tuberculosisInternational Journal of Infectious Diseases, 2015
- Metaprop: a Stata command to perform meta-analysis of binomial dataArchives of Public Health, 2014
- Treatment Outcomes for Patients with Multidrug-Resistant Tuberculosis in Post-Earthquake Port-au-Prince, HaitiThe American Journal of Tropical Medicine and Hygiene, 2014
- Adverse Events in an Integrated Home-Based Treatment Program for MDR-TB and HIV in KwaZulu-Natal, South AfricaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Use of Anti-Retroviral Therapy in Tuberculosis Patients on Second-Line Anti-TB Regimens: A Systematic ReviewPLOS ONE, 2012
- Adverse effects profile of multidrug-resistant tuberculosis treatment in a South African outpatient clinicSouth African Family Practice, 2012
- Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysisJournal of Antimicrobial Chemotherapy, 2012
- Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, IndiaPLOS ONE, 2012
- Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis [Review article]The International Journal of Tuberculosis and Lung Disease, 2012